Vilon

Vilon (Lys-Glu, also called lysylglutamate or KE) is a synthetic dipeptide, meaning it is a tiny protein fragment made from just two amino acids: lysine and glutamate. It belongs to the group of Khavinson bioregulators. Vladimir Khavinson and his team at the St. Petersburg Institute of Bioregulation and Gerontology developed it. The substance was originally found as one of the active parts of Thymalin extract, which comes from the thymus of cattle [1]. Vilon targets the thymus, the organ behind your breastbone where T-lymphocytes (a type of white blood cell) mature.

Vilon is very small, with a molecular weight of 275 Da, which makes it one of the smallest bioactive peptides. Because it is so short, it could in theory be taken orally. However, there is not a single controlled clinical human study and no regulatory drug approval for this peptide to this day [1][2][3]. All published findings come from animal and cell culture experiments, and almost all of them were published by the Russian developer group itself.

How is Vilon used?

In animal experiments, Vilon is mostly injected under the skin (subcutaneously). On the market, you find oral capsules sold as dietary supplements, and on the gray market, freeze-dried powder for mixing with BAC water [3]. Some vendors also sell sublingual forms (drops under the tongue), but there is no scientific validation for these in humans at all.

Subcutaneous injection is the only route that has been studied in animal trials. Oral forms exist only as unregulated dietary supplements without clinical evidence that they work. For none of these forms is there a validated human dose from controlled dose-finding studies. The amounts you see circulating come only from lab protocols or vendor recommendations [1].

These dose figures are a purely descriptive documentation from publications and market offerings, not a dosing instruction. For Vilon, there is no dosage proven to be effective or safe in humans in clinical studies.

From vial to use: reconstitution and the math

Reconstituting lyophilized Vilon powder (typical vial sizes: 5 mg, 10 mg, or 20 mg) means dissolving the peptide in a sterile carrier liquid such as BAC water (bacteriostatic water, which stops bacteria from growing). A detailed step-by-step guide is available in the guide to mixing and storing.

Here is a worked example for reconstituting a 5 mg vial with BAC water:

A 5 mg vial of Vilon, at a dose of 100 µg per day, mathematically yields 50 single doses. That is enough for 50 days or five 10-day cycles. The reconstituted peptide solution must be stored in the refrigerator at 2-8 °C and used within 28 days. This procedure reflects a user practice that has not been clinically tested.

Unverified user practice: On the gray market, 1 ml of BAC water is sometimes used for a 5 mg vial (concentration 5 mg/ml), which halves the syringe volumes. The choice of volume is practical, not evidence-based.

How does Vilon work?

The proposed mechanism of action for Vilon covers three areas: the growth of thymic progenitor cells, an increase in interleukin-2, and epigenetic decondensation processes in the cell nucleus. Here is what the research on each level shows:

• Thymocyte proliferation: In mouse models, Vilon stimulated the cell division of T-cell precursors (thymocytes) and raised the proliferation index after irradiation from 26% to 37%. That made it the strongest mitogen (a substance that triggers cell division) among the Khavinson peptides tested [1][3].
• IL-2 gene expression: In mouse spleen cells, Vilon induced the mRNA synthesis of the cytokine interleukin-2 (IL-2), which acts as a central growth factor for T-lymphocytes [4].
• Chromatin reactivation: In ex-vivo cultured lymphocytes from elderly people, Vilon caused the unfolding of condensed chromatin (deheterochromatinization) and reactivated previously inactive ribosomal genes [2][6].

The observed chromatin unfolding hints at a possible cellular reactivation of aging DNA sections, but it is purely an in-vitro finding. This deheterochromatinization effect has only been shown in isolated cell cultures and has not yet been replicated by any independent research group outside the developer team [2].

What does the research show?

The scientific evidence on Vilon splits into four parts: preclinical animal models, in-vitro cell cultures, ex-vivo human analyses, and the complete absence of controlled clinical phase studies. Here is what each part tells us:

Animal studies

In an animal experimental study on CBA mice, chronic subcutaneous injection of Vilon led to extended lifespan, a reduced rate of spontaneous tumors, and improved biological aging markers [3]. However, these data come from a single research institute and have not been replicated by independent studies.

Cell culture studies

In-vitro experiments show that Vilon promotes the differentiation of T-cells in human and animal thymus cell cultures [5] and stimulates the mRNA expression of IL-2 in spleen cells [4]. In thymic epithelial cells, the peptide also led to increased expression of nucleolus organizer region proteins as a marker of increased ribosomal activity [5].

Ex-vivo human data

In a human ex-vivo study by Lezhava et al., isolated lymphocytes from 27 elderly subjects (76-81 years) and 8 younger controls (26-35 years) were incubated with Vilon. In the cells of the seniors, the treatment led to a significant loosening of age-related condensed chromatin and reactivated ribosomal genes [2][6].

These ex-vivo findings come from blood cells outside the human body and do not prove biological effectiveness in a living organism. Cell culture results do not allow reliable conclusions about either therapeutic effectiveness or toxicological safety in humans.

Clinical studies

For Vilon, there is not a single controlled clinical study in humans and no entry in registries such as ClinicalTrials.gov. The dipeptide has neither FDA nor EMA approval and is registered in Russia only as a dietary supplement, not as a drug [1].

What risks and side effects are known?

For Vilon, there are no systematic safety data in humans from standardized clinical trials. The developers report good tolerability for related thymus preparations (Thymalin, Thymogen) in Russian practice [1], but this does not meet modern pharmacological safety and pharmacovigilance standards.

When using Vilon, you should consider the following risk areas:

• Injection risks: With subcutaneous use of research chemicals, the usual risks apply - injection reactions, infections from non-sterile handling, unknown contaminants.
• Unknown purity: Products from the gray market are not subject to regulatory control; purity and peptide content (HPLC, mass spectrometry) must be documented via independent certificates of analysis (CoA). The guide Protection when ordering provides criteria for evaluating vendors.
• Immunomodulation: Sustained stimulation of T-cell signaling pathways carries theoretical risks of immunological misregulation or autoimmune reactions, as long-term toxicological data are lacking.
• Interactions: Potential interactions with other drugs, especially with immunosuppressants or immunostimulants, have not been scientifically investigated.

What is still unknown?

• Clinical human studies: Effectiveness and safety in humans have not been demonstrated in any controlled clinical trials.
• Independent replication: The published animal and cell culture data come almost exclusively from Khavinson's research group and have not been independently confirmed.
• Human pharmacokinetics: Elimination half-life, subcutaneous and oral bioavailability, and metabolic pathways in the human body are untested.
• Tested dose finding: There are no dose-response studies to determine a therapeutically effective and safe human dose.
• Ex-vivo to in-vivo transfer: Whether the chromatin effects shown in the lab can be reproduced in intact human tissue remains unclear.
• Long-term safety: Results on the lifespan of mice cannot be transferred to humans; long-term data on human use do not exist.

Vilon in the context of the Khavinson peptides

Vilon belongs to the group of synthetic short peptides that Khavinson developed from tissue extracts. This group also includes Epithalon (from the pineal gland) as well as Thymosin Alpha-1, which is approved as a drug in several countries. In the mouse study, the combination of Vilon and Epithalon showed an increased number of altered genes (144 vs. 36 with Vilon alone) [3], but this remains a purely experimental research approach.

In the peptide library, you will find profiles of related active substances and peptide structures. In addition, the glossary explains key technical terms such as bioavailability, half-life, or reconstitution in an understandable and detailed way.